Ascorbic acid kills Epstein–Barr virus positive Burkitt lymphoma cells and Epstein–Barr virus transformed B-cells in vitro, but not in vivo

References

• Keller SA, Hernandez-Hopkins D, Vider J, . NF-kappaB is essential for the progression of KSHV- and EBV-infected lymphomas in vivo. Blood 2006;107:3295–3302.
   PubMed Web of Science ®Google Scholar
• Cohen JI. Epstein-Barr virus infection. N Engl J Med 2000;343: 481–492.
   PubMed Web of Science ®Google Scholar
• Cohen JI, Bollard CM, Khanna R, . Current understanding of the role of Epstein-Barr virus in lymphomagenesis and therapeutic approaches to EBV-associated lymphomas. Leuk Lymphoma 2008; 49(Suppl. 1):27–34.
   PubMed Web of Science ®Google Scholar
• Imai S, Koizumi S, Sugiura M, . Gastric carcinoma: monoclonal epithelial malignant cells expressing Epstein-Barr virus latent infection protein. Proc Natl Acad Sci USA 1994;91:9131–9135.
   PubMed Web of Science ®Google Scholar
• Sugiura M, Imai S, Tokunaga M, . Transcriptional analysis of Epstein-Barr virus gene expression in EBV-positive gastric carcinoma: unique viral latency in the tumour cells. Br J Cancer 1996;74: 625–631.
   PubMed Web of Science ®Google Scholar
• Pallesen G, Hamilton-Dutoit SJ, Rowe M, . Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet 1991;337:320–322.
   PubMed Web of Science ®Google Scholar
• Pathmanathan R, Prasad U, Sadler R, . Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N Engl J Med 1995;333:693–698.
   PubMed Web of Science ®Google Scholar
• Chiang AK, Tao Q, Srivastava G, . Nasal NK- and T-cell lymphomas share the same type of Epstein-Barr virus latency as nasopharyngeal carcinoma and Hodgkin's disease. Int J Cancer 1996;68:285–290.
   PubMed Web of Science ®Google Scholar
• Chen CL, Sadler RH, Walling DM, . Epstein-Barr virus (EBV) gene expression in EBV-positive peripheral T-cell lymphomas. J Virol 1993;67:6303–6308.
   PubMed Web of Science ®Google Scholar
• Cohen JI. Epstein-Barr virus lymphoproliferative disease associated with acquired immunodeficiency. Medicine (Baltimore) 1991;70:137–160.
   PubMed Web of Science ®Google Scholar
• MacMahon EM, Glass JD, Hayward SD, . Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet 1991;338:969–973.
   PubMed Web of Science ®Google Scholar
• Rea D, Delecluse HJ, Hamilton-Dutoit SJ, . Epstein-Barr virus latent and replicative gene expression in post-transplant lymphoproliferative disorders and AIDS-related non-Hodgkin's lymphomas. French Study Group of Pathology for HIV-associated Tumors. Ann Oncol 1994;5(Suppl. 1):113–116.
   PubMedGoogle Scholar
• Hamilton-Dutoit SJ, Rea D, Raphael M, . Epstein-Barr virus-latent gene expression and tumor cell phenotype in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Correlation of lymphoma phenotype with three distinct patterns of viral latency. Am J Pathol 1993;143:1072–1085.
   PubMed Web of Science ®Google Scholar
• Zou P, Kawada J, Pesnicak L, . Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells. J Virol 2007;81: 10029–10036.
   PubMed Web of Science ®Google Scholar
• Cahir-McFarland ED, Carter K, Rosenwald A, . Role of NF-kappa B in cell survival and transcription of latent membrane protein 1-expressing or Epstein-Barr virus latency III-infected cells. J Virol 2004;78:4108–4119.
   PubMed Web of Science ®Google Scholar
• Katano H, Pesnicak L, Cohen JI. Simvastatin induces apoptosis of Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines and delays development of EBV lymphomas. Proc Natl Acad Sci USA 2004;101:4960–4965.
   PubMed Web of Science ®Google Scholar
• Lassoued S, Ben Ameur R, Ayadi W, . Epstein-Barr virus induces an oxidative stress during the early stages of infection in B lymphocytes, epithelial, and lymphoblastoid cell lines. Mol Cell Biochem 2008;313:179–186.
   PubMed Web of Science ®Google Scholar
• Osipova-Goldberg HI, Turchanowa LV, Adler B, . H2O2 inhibits BCR-dependent immediate early induction of EBV genes in Burkitt's lymphoma cells. Free Radic Biol Med 2009;47:1120–1129.
   PubMed Web of Science ®Google Scholar
• Chen Q, Espey MG, Krishna MC, . Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci USA 2005;102:13604–13609.
   PubMed Web of Science ®Google Scholar
• Chen Q, Espey MG, Sun AY, . Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci USA 2008;105:11105–11109.
   PubMed Web of Science ®Google Scholar
• Verrax J, Calderon PB. Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects. Free Radic Biol Med 2009;47:32–40.
   PubMed Web of Science ®Google Scholar
• Ohno S, Ohno Y, Suzuki N, . High-dose vitamin C (ascorbic acid) therapy in the treatment of patients with advanced cancer. Anticancer Res 2009;29:809–815.
   PubMed Web of Science ®Google Scholar
• Levine M, Padayatty SJ, Espey MG. Vitamin C: a concentration-function approach yields pharmacology and therapeutic discoveries. Adv Nutr 2011;2:78–88.
   PubMed Web of Science ®Google Scholar
• Monti DA, Mitchell E, Bazzan AJ, . Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS One 2012;7:e29794.
   PubMed Web of Science ®Google Scholar
• Kawada J, Zou P, Mazitschek R, . Tubacin kills epstein-barr virus (EBV)-Burkitt lymphoma cells by inducing reactive oxygen species and EBV lymphoblastoid cells by inducing apoptosis. J Biol Chem 2009;284:17102–17109.
   PubMed Web of Science ®Google Scholar
• Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27–55.
   PubMedGoogle Scholar
• Washko PW, Welch RW, Dhariwal KR, . Ascorbic acid and dehydroascorbic acid analyses in biological samples. Anal Biochem 1992;204:1–14.
   PubMed Web of Science ®Google Scholar
• Nakano A, Abe M, Oda A, . Delayed treatment with vitamin C and N-acetyl-L-cysteine protects Schwann cells without compromising the anti-myeloma activity of bortezomib. Int J Hematol 2011;93: 727–735.
   PubMed Web of Science ®Google Scholar
• Rowe M, Young LS, Crocker J, . Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man. J Exp Med 1991;173:147–158.
   PubMed Web of Science ®Google Scholar
• Feng WH, Kenney SC. Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression. Cancer Res 2006;66:8762–8769.
   PubMed Web of Science ®Google Scholar
• Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?Nat Rev Drug Discov 2009;8:579–591.
   PubMed Web of Science ®Google Scholar
• Chen Q, Espey MG, Sun AY, . Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci USA 2007;104:8749–8754.
   PubMed Web of Science ®Google Scholar
• Bannerman B, Xu L, Jones M, . Preclinical evaluation of the antitumor activity of bortezomib in combination with vitamin C or with epigallocatechin gallate, a component of green tea. Cancer Chemother Pharmacol 2011;68:1145–1154.
   PubMed Web of Science ®Google Scholar
• Perrone G, Hideshima T, Ikeda H, . Ascorbic acid inhibits antitumor activity of bortezomib in vivo. Leukemia 2009;23:1679–1686.
   PubMed Web of Science ®Google Scholar
• Zou W, Yue P, Lin N, . Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells. Clin Cancer Res 2006;12:273–280.
   PubMed Web of Science ®Google Scholar